Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes

被引:344
作者
Dukkipati, Srinivas R. [1 ]
Kar, Saibal [2 ]
Holmes, David R. [3 ]
Doshi, Shephal K. [4 ]
Swarup, Vijendra [5 ]
Gibson, Douglas N. [6 ]
Maini, Brijeshwar [7 ]
Gordon, Nicole T. [8 ]
Main, Michael L. [9 ]
Reddy, Vivek Y. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Mayo Clin, Rochester, MN USA
[4] Pacific Heart Inst, Santa Monica, CA USA
[5] Arizona Heart Rhythm Ctr, Phoenix, AZ USA
[6] Scripps Clin, La Jolla, CA 92037 USA
[7] Delray Med, Delray Beach, FL USA
[8] Boston Sci Corp, St Paul, MN USA
[9] Univ Missouri, Kansas City, MO 64110 USA
关键词
atrial appendage; atrial fibrillation; percutaneous coronary intervention; stroke; thrombosis; AMPLATZER CARDIAC PLUG; WATCHMAN LAA CLOSURE; EMBOLIC PROTECTION; WARFARIN THERAPY; FIBRILLATION; STROKE; TRIAL; PREVENTION; OCCLUSION; EFFICACY;
D O I
10.1161/CIRCULATIONAHA.118.035090
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation. Methods: We studied the device arms of 4 prospective Food and Drug Administration trials: PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA(2)DS(2)-VASC and HAS-BLED scores. Results: Of 1739 patients who received an implant (7159 patient-years follow-up; CHA(2)DS(2)-VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18-5.79; P<0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90-5.45, P<0.001). On multivariable modeling analysis, the predictors of DRT were as follows: history of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26-4.25; P=0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19-4.20; P=0.012); vascular disease (OR, 2.06; 95% CI, 1.08-3.91; P=0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01-1.12; P=0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94-0.99; P=0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT. Conclusions: After left atrial appendage closure with Watchman, DRT (approximate to 3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.
引用
收藏
页码:874 / 885
页数:12
相关论文
共 21 条
[1]   Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study [J].
Bergmann, Martin W. ;
Ince, Huseyin ;
Kische, Stephan ;
Schmitz, Thomas ;
Meincke, Felix ;
Schmidt, Boris ;
Foley, David ;
Betts, Timothy R. ;
Grygier, Marek ;
Protopopov, Alexey V. ;
Stein, Kenneth M. ;
Boersma, Lucas V. A. .
EUROINTERVENTION, 2018, 13 (17) :2003-2011
[2]  
Bergmann MW, 2017, EUROINTERVENTION, V13, P877, DOI 10.4244/EIJ-D-17-00042
[3]   Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication [J].
Boersma, Lucas V. ;
Barr, Craig S. ;
Burke, Martin C. ;
Leon, Angel R. ;
Theuns, Dominic A. ;
Herre, John M. ;
Weiss, Raul ;
Kremers, Mark S. ;
Neuzil, Petr ;
Husby, Michael P. ;
Carter, Nathan ;
Stivland, Timothy M. ;
Gold, Michael R. .
HEART RHYTHM, 2017, 14 (03) :367-375
[4]  
Boersma LVA, 2018, STROKE BLEEDING MORT
[5]   Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device [J].
Enomoto, Yoshinari ;
Gadiyaram, Varuna K. ;
Gianni, Carola ;
Horton, Rodney P. ;
Trivedi, Chintan ;
Mohanty, Sanghamitra ;
Di Biase, Luigi ;
Al-Ahmad, Amin ;
Burkhardt, J. David ;
Narula, Arvin ;
Janczyk, Gwen ;
Price, Matthew J. ;
Afzal, Muhammad R. ;
Atoui, Moustapha ;
Earnest, Matthew ;
Swarup, Vijay ;
Doshi, Shephal K. ;
van der Zee, Sarina ;
Fisher, Rebecca ;
Lakkireddy, Dhanunjaya R. ;
Gibson, Douglas N. ;
Natale, Andrea ;
Reddy, Vivek Y. .
HEART RHYTHM, 2017, 14 (01) :19-24
[6]   Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation [J].
Fauchier, Laurent ;
Cinaud, Alexandre ;
Brigadeau, Francois ;
Lepillier, Antoine ;
Pierre, Bertrand ;
Abbey, Selim ;
Fatemi, Marjaneh ;
Franceschi, Frederic ;
Guedeney, Paul ;
Jacon, Peggy ;
Paziaud, Olivier ;
Venier, Sandrine ;
Deharo, Jean Claude ;
Gras, Daniel ;
Klug, Didier ;
Mansourati, Jacques ;
Montalescot, Gilles ;
Piot, Olivier ;
Defaye, Pascal .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (14) :1528-1536
[7]   Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study [J].
Friberg, Leif ;
Rosenqvist, Marten ;
Lip, Gregory Y. H. .
EUROPEAN HEART JOURNAL, 2012, 33 (12) :1500-+
[8]   Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial [J].
Holmes, David R. ;
Reddy, Vivek Y. ;
Turi, Zoltan G. ;
Doshi, Shephal K. ;
Sievert, Horst ;
Buchbinder, Maurice ;
Mullin, Christopher M. ;
Sick, Peter .
LANCET, 2009, 374 (9689) :534-542
[9]   Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation A Patient-Level Meta-Analysis [J].
Holmes, David R., Jr. ;
Doshi, Shephal K. ;
Kar, Saibal ;
Price, Matthew J. ;
Sanchez, Jose M. ;
Sievert, Horst ;
Valderrabano, Miguel ;
Reddy, Vivek Y. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (24) :2614-2623
[10]   Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy [J].
Holmes, David R., Jr. ;
Kar, Saibal ;
Price, Matthew J. ;
Whisenant, Brian ;
Sievert, Horst ;
Doshi, Shephal K. ;
Huber, Kenneth ;
Reddy, Vivek Y. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (01) :1-12